Vanguard Global Advisers
CSBR icon

Vanguard Global Advisers’s Champions Oncology CSBR Stock Holding History

Vanguard Global Advisers’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Hold
2,093
– – ﹤0.01% 3431
2026
Q1 		$12K Buy
+2,093
New +$13.3K ﹤0.01% 3450

Other funds holding CSBR

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Global Advisers's CSBR Position: Q2 2026 in Review

Vanguard Global Advisers held its Champions Oncology (CSBR) position steady in Q2 2026 at 2,093 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Vanguard Global Advisers first reported a position in CSBR in Q1 2026 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.

  • Vanguard Global Advisers held 2,093 shares of Champions Oncology worth $12.9K as of Q2 2026.
  • Vanguard Global Advisers left its Champions Oncology share count unchanged in Q2 2026.
  • Champions Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3431 holding.
  • Vanguard Global Advisers first reported a position in Champions Oncology in Q1 2026 and has held it in 2 quarters since.
  • 23 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.